

## Cincinnati, Ohio — 2003 (N=275)

Figure A. Age of GISP participants, in years, 2003




Figure B. Race/ethnicity of GISP participants, 2003




Figure C. Percentage of GISP participants identifying as men who have sex with men, 1988–2003






Figure D. Reason for visit among GISP participants, 2003



## Cincinnati, Ohio — 2003 (N=275)

**Figure E. Previous episode of gonorrhea among GISP participants, 1991–2003**




\*Data first collected in 1991.


\*\*Data first collected in 1992.

Note: Data points not shown when >30% data missing.


**Figure F. Drugs used to treat gonorrhea among GISP participants, 2003**



**Figure G. Drugs used to treat *Chlamydia trachomatis* infection among GISP participants, 2003**




**Figure H. Resistance to penicillin and tetracycline among GISP isolates, 2003**




## Cincinnati, Ohio — 2003 (N=275)


**Figure I. Decreased susceptibility to ceftriaxone among GISP isolates, 1988–2003**



**Figure J. Decreased susceptibility to cefixime among GISP isolates, 1992–2003**




**Figure K. Intermediate resistance and resistance to ciprofloxacin among GISP isolates, 1990–2003**



Note: Susceptibility to ciprofloxacin first measured in 1990.

**Figure L. Decreased susceptibility to azithromycin among GISP isolates, 1992–2003**



Note: Susceptibility to azithromycin first measured in 1992.

Note: Decreased susceptibility to azithromycin is defined here as  $\geq 1.0 \mu\text{g/ml}$ .  
No NCCLS criteria currently exist.